Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase
- 作者: Vinogradova O.Y.1, Turkina A.G.1, Vorontsova A.V.1, Chelysheva E.Y.1, Gusarova G.A.1, Kuznetsov SV1, Goryacheva S.R.1, Sokolova M.A.1, Abakumov E.M.1, Stakhina O.V.1, Domracheva E.V.1, Misyurin A.V.1, Khoroshko N.D.1, Vinogradova OY.1, Turkina AG1, Vorontsova AV1, Chelysheva EY.1, Gusarova GA1, Kuznetsov SV1, Goryacheva SR1, Sokolova MA1, Abakumov EM1, Stakhina OV1, Domracheva EV1, Misyurin AV1, Khoroshko ND1
-
隶属关系:
- 期: 卷 81, 编号 7 (2009)
- 页面: 41-46
- 栏目: Editorial
- ##submission.dateSubmitted##: 09.04.2020
- ##submission.datePublished##: 15.07.2009
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30380
- ID: 30380
如何引用文章
全文:
详细
Material and methods. A total of 18 patients with chronic myeloid leukemia (CML) in a chronic stage received dasatinib for 9-30 months (median 30 months) to September 2008.
Results. Lethal outcomes during dasatinib treatment were absent. To September 2008, 16(89%) patients were alive, 2(11%) patients died of the disease progression after dasatinib discontinuation. A complete clinicohematological response was observed in all the patients. Major cytogenetic, complete cytogenetic, major molecular, complete molecular responses were achieved in 12(67%), 10(55%), 7(39%) and 5(28%) patients, respectively. Hematological and non-hematological toxicity occurred in 9(50%) patients. Now 12(67%) patients continue dasatinib treatment, in 6(33%) patients the drug was discontinued.
Conclusion. The results from trials in Russian Hematological Research Center are the same as in the international study. Dasatinib is effective and well tolerated therapeutic option for imatinib-resistant patients with a chronic phase of CML.
作者简介
Ol'ga Vinogradova
Email: olgavinz@mail.ru
Anna Turkina
Email: tur@blood.ru
Aleksandra Vorontsova
Email: voroncova9@mail.ru
Ekaterina Chelysheva
Email: denve@bk.ru
Galina Gusarova
Email: galina1966@bk.ru
S Kuznetsov
Svetlana Goryacheva
Manana Sokolova
Email: manana@mail.ru
Evgeniy Abakumov
Ol'ga Stakhina
Email: stakhina@mail.ru
Elena Domracheva
Email: dom@blood.ru
Andrey Misyurin
Nina Khoroshko
Email: khoroshko@blood.ru
O Vinogradova
A Turkina
A Vorontsova
E Chelysheva
G Gusarova
S Kuznetsov
S Goryacheva
M Sokolova
E Abakumov
O Stakhina
E Domracheva
A Misyurin
N Khoroshko
参考
- Kantarjian H., Pasquini R., Hamerschlak N. et al. Dasatinib or high-dose imatinib for with chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007; 109 (12): 5143-5150.
- Stephen G., O'Brien S. G., Guilhot F. et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate, of transformation and increased rate of major molecular response in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with Imatinib. Blood 2008; 112 (11): 76, abstr. 186.
- Shah N. P. DASATINIB. Drugs of Today 2007; 43 (1): 5-12.
- Shah N. P., Tran C., Lee F. Y. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
- Donato N. Activity of a novel turosine kinase inhibitor BMS-354825 on STI571 sensitive and resistant CML cells. Bristol-Myers Squibb, Jan 02, 2003. BMS Document Control N. 930003220.
- O'Harre T., Walters D. K., Stoffregen E. P. et al. Com-bind Abl inhibition therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin. Cancer Res. 2005; 11: 6987-6993.
- Tokarski J., Newitt J., Lee F. The crustal structure of ABL kinase with BMS-354825, a dual SRC/ABL kinase inhibitor. Blood 2004; 104: 160a.
- Sokal J. E., Cox E. B., Baccarani M. et al. Blood 1984; 63; 789-799.
- Туркина А. Г. Клиническое значение молекулярно-генетических и иммунофенотипических характеристик хронического миелолейкоза: Автореф. дис. ... д-ра мед. наук. 1998.
- Baccarani M. et al. Haematologica 2008; 93: 161-169.